Grant: Master's Award: Canada Graduate Scholarships
University of Guelph
$17,500.00
Canadian graduate scholarship funding application
EF 2013-14
Résumé
I am applying for a Canadian Graduate Scholarship in hopes of acquiring funding to continue my current research. My research focuses on lung cancer and molecular targets for therapeutic drugs. Lung cancer is the second most commonly diagnosed cancer in Canada, and has the highest cancer related mortality in the world [1]. In Canada, the incidence rate is very similar to the death rate, which means that the mortality rate for this cancer is very high. These statistics show us that it is very important to identify more efficient therapies that can potentially treat this disease.
Generally, there are two classifications of lung cancer based on appearance of cells; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC constitutes approximately 85% of lung cancers and can be further classified as squamous cell carcinoma, adenocarcinoma and large cell carcinoma [2]. Currently, surgical removal of tumors is considered to be the best treatment for NSCLC, and is usually paired with radiotherapy or chemotherapy depending on the stage of the disease. In efforts to improve treatment, recent research has identified many molecular based therapies, which have undergone clinical trials.
One intracellular signaling molecule that is currently being studied is Akt, which is involved in regulating cell growth, metabolism, proliferation, survival, and migration. Hyper-activation of Akt signaling is seen in more than 70% of NSCLC cases. Furthermore, research has shown that activation of Akt is associated with poor prognosis. The only Akt inhibitor that has undergone clinical trials is MK-2206, which inhibits all three isoforms of Akt (1-3) [3]. It was previously thought that the three isomers have similar functions, however recently it has been speculated that Akt 1 and Akt 2 may work antagonistically, while the role of Akt 3 is still uncertain. Dr. Moorehead's lab found that the loss of Akt1 inhibits tumor formation in the lungs while loss of Akt2 enhances tumor formation. Since loss of Akt2 promotes lung tumorigenesis, agents that non-selectively target both Akt1 and Akt2 may be less effective at inhibiting lung tumorigenesis than agents that selectively target Akt1.
My current experimental plan involves evaluating the efficacy of Akt 1 selective inhibitors on NSCLC cell lines, and comparing it to Akt 2 selective and pan Akt inhibitors. I am currently in the process of gathering data from dose response curves in order to determine cell survival and appropriate dosage of these inhibitors. Next I will determine the specificities of these inhibitors to ensure that the molecules being detected are in fact the right ones. I will then proceed to evaluate the effects of combining these inhibitors with two platinum chemotherapeutic drugs, cisplatin and carboplatin. These results will help us determine if targeting one specific isoform of Akt would be an effective therapeutic strategy, alone or in combination with chemotherapeutic agents. There is also potential to extrapolate this data and proceed with this research with in-vivo models. This will allow us to see if the same effects are observed in both cell lines and organisms.
References
[1]""Lung cancer statistics."" www.cancer.ca, 2013. Web. 2 Dec 2013. <http://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region=on>.
[2]Wood, D., Eapen, G., Ettinger, D., Hou, L., Jackman, D., Kazerooni, E., Klippenstein, D., Lackner, R., Leard, L., Leung, A. and Others: Lung cancer screening. Journal of the National Comprehensive Cancer Network 2012, 10(2): 240-265.
[3]Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ: Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoSOne 2012, 7(7):e41593.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311905
Name
Briah Ritesh
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canadian graduate scholarship funding application
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Akt Inhibitors; Chemotherapeutics; In-Vitro; Lung Cancer; Non Small Cell Lung Cancer; Pan Akt; Proliferation; Selective Akt1; Survival; Treatment
Abstract
I am applying for a Canadian Graduate Scholarship in hopes of acquiring funding to continue my current research. My research focuses on lung cancer and molecular targets for therapeutic drugs. Lung cancer is the second most commonly diagnosed cancer in Canada, and has the highest cancer related mortality in the world [1]. In Canada, the incidence rate is very similar to the death rate, which means that the mortality rate for this cancer is very high. These statistics show us that it is very important to identify more efficient therapies that can potentially treat this disease.
Generally, there are two classifications of lung cancer based on appearance of cells; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC constitutes approximately 85% of lung cancers and can be further classified as squamous cell carcinoma, adenocarcinoma and large cell carcinoma [2]. Currently, surgical removal of tumors is considered to be the best treatment for NSCLC, and is usually paired with radiotherapy or chemotherapy depending on the stage of the disease. In efforts to improve treatment, recent research has identified many molecular based therapies, which have undergone clinical trials.
One intracellular signaling molecule that is currently being studied is Akt, which is involved in regulating cell growth, metabolism, proliferation, survival, and migration. Hyper-activation of Akt signaling is seen in more than 70% of NSCLC cases. Furthermore, research has shown that activation of Akt is associated with poor prognosis. The only Akt inhibitor that has undergone clinical trials is MK-2206, which inhibits all three isoforms of Akt (1-3) [3]. It was previously thought that the three isomers have similar functions, however recently it has been speculated that Akt 1 and Akt 2 may work antagonistically, while the role of Akt 3 is still uncertain. Dr. Moorehead's lab found that the loss of Akt1 inhibits tumor formation in the lungs while loss of Akt2 enhances tumor formation. Since loss of Akt2 promotes lung tumorigenesis, agents that non-selectively target both Akt1 and Akt2 may be less effective at inhibiting lung tumorigenesis than agents that selectively target Akt1.
My current experimental plan involves evaluating the efficacy of Akt 1 selective inhibitors on NSCLC cell lines, and comparing it to Akt 2 selective and pan Akt inhibitors. I am currently in the process of gathering data from dose response curves in order to determine cell survival and appropriate dosage of these inhibitors. Next I will determine the specificities of these inhibitors to ensure that the molecules being detected are in fact the right ones. I will then proceed to evaluate the effects of combining these inhibitors with two platinum chemotherapeutic drugs, cisplatin and carboplatin. These results will help us determine if targeting one specific isoform of Akt would be an effective therapeutic strategy, alone or in combination with chemotherapeutic agents. There is also potential to extrapolate this data and proceed with this research with in-vivo models. This will allow us to see if the same effects are observed in both cell lines and organisms.
References
[1]""Lung cancer statistics."" www.cancer.ca, 2013. Web. 2 Dec 2013. <http://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region=on>.
[2]Wood, D., Eapen, G., Ettinger, D., Hou, L., Jackman, D., Kazerooni, E., Klippenstein, D., Lackner, R., Leard, L., Leung, A. and Others: Lung cancer screening. Journal of the National Comprehensive Cancer Network 2012, 10(2): 240-265.
[3]Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ: Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoSOne 2012, 7(7):e41593.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Briah, Ritesh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~